



CD26 and Cancer

Guest Editor:

Prof. Dr. Oscar J. Cordero

1. Department of Biochemistry and Molecular Biology, CIBUS Building, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain

2. Gene Regulatory Control in Disease Group, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain

3. Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain

Deadline for manuscript submissions:

closed (30 September 2021)

Message from the Guest Editor

Dear Colleagues,

There are several issues not yet known about CD26, although its enzymatic activity is a well-known target in diabetes treatments.

On one side, it has been proposed that CD4+ T cell subsets with CD26 show properties critical for improving cancer immunotherapy, as they have a rich chemokine receptor profile, profound cytotoxicity, resistance to apoptosis, enhanced stemness, and the capacity to regress and survive in solid tumours.

On the other side, the subsets of cancer stem cells expressing CD26 are known to be implicated in metastasis. Both branches of research match CD26 in enhanced migration and cell persistence.

Some advances have also been made on the role of the soluble form of CD26, which has been proposed as a biomarker of, mainly, lung and colorectal cancer, as well as on the existence of autoantibodies against CD26. The relationships between all these participants, however, are yet not well understood.

Prof. Oscar J. Cordero
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)